Search

Your search keyword '"Olli Carpén"' showing total 300 results

Search Constraints

Start Over You searched for: Author "Olli Carpén" Remove constraint Author: "Olli Carpén"
300 results on '"Olli Carpén"'

Search Results

1. Infective SARS-CoV-2 in Skull Sawdust at Autopsy, Finland

2. Venous thromboembolism incidence and association with overall survival in pancreatic cancer: A Finnish nationwide cohort study

3. PIK3R1 fusion drives chemoresistance in ovarian cancer by activating ERK1/2 and inducing rod and ring-like structures

4. Data-driven comorbidity analysis of 100 common disorders reveals patient subgroups with differing mortality risks and laboratory correlates

5. APOE ε4 associates with increased risk of severe COVID-19, cerebral microhaemorrhages and post-COVID mental fatigue: a Finnish biobank, autopsy and clinical study

6. Screening for potential undiagnosed Gaucher disease patients: Utilisation of the Gaucher earlier diagnosis consensus point-scoring system (GED-C PSS) in conjunction with electronic health record data, tissue specimens, and small nucleotide polymorphism (SNP) genotype data available in Finnish biobanks

7. Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status

8. Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance

9. Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality

10. Multiple formin proteins participate in glioblastoma migration

11. DNA methylation and Transcriptome Changes Associated with Cisplatin Resistance in Ovarian Cancer

12. BRAF immunohistochemistry predicts sentinel lymph node involvement in intermediate thickness melanomas.

13. Formin Proteins FHOD1 and INF2 in Triple-Negative Breast Cancer: Association With Basal Markers and Functional Activities

14. Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer.

15. Multistep Phosphorylation by Oncogenic Kinases Enhances the Degradation of the NF2 Tumor Suppressor Merlin

16. Heterogeneous EGFR gene copy number increase is common in colorectal cancer and defines response to anti-EGFR therapy.

17. FHOD1, a formin upregulated in epithelial-mesenchymal transition, participates in cancer cell migration and invasion.

18. MMP-13 regulates growth of wound granulation tissue and modulates gene expression signatures involved in inflammation, proteolysis, and cell viability.

21. FUNGI: FUsioN Gene Integration toolset.

24. Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

27. Risk of Midlife Stroke After Adverse Pregnancy Outcomes: The FinnGen Study

28. A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids

29. Evolutionary states and trajectories characterized by distinct pathways stratify patients with ovarian high grade serous carcinoma

30. Endothelial Pim3 kinase protects the vascular barrier during lung metastasis

31. New insights into the genetic etiology of Alzheimer's disease and related dementias

32. Supplementary Figure S5. from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

33. Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

34. Data from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes

36. Supplementary methods from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative

38. Supplementary figure 4 from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative

39. Supplementary figure 2 from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative

40. Supplementary figure 3 from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative

41. Data from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative

42. Supplementary data from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative

43. Data from Mathematical Modeling Predicts Response to Chemotherapy and Drug Combinations in Ovarian Cancer

44. Supplementary figure 1 from Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas—an ENITEC Group Initiative

45. Supplementary Figures 1 - 9, Tables 1 - 6 from Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum–Taxane Chemotherapy

46. Supplementary Data from Analysis of the Human Cancer Glycome Identifies a Novel Group of Tumor-Associated N-Acetylglucosamine Glycan Antigens

47. A single-cell atlas of human fetal lung development between 14 and 19 weeks of gestation

48. Evolutionary states and trajectories characterized by distinct pathways stratify ovarian high-grade serous carcinoma patients

49. Co-evolution of matrisome and adaptive adhesion dynamics drives ovarian cancer chemoresistance

50. PRISM: recovering cell-type-specific expression profiles from individual composite RNA-seq samples

Catalog

Books, media, physical & digital resources